Maximizing Emerging Technology’s
Potential
Chris L. Waller, Ph.D.
October 2011
1
Outline
• Industry Drivers for Change
– Vertical Disintegration and Selective Sourcing
• The Pistoia Alliance
– A Pre-competitive Technology Development Experiment
• eHealth
– A Transformative Opportunity for Pharma Driven by Emerging
Technologies
• Pharma 2.0
– The Emerging Research Alliance Network Model and The
Importance of Technology Partners
R&D: Long, Expensive, and Risky
Target
Selection
Chemical
Selection
Clinical
Trials
Launch
Discovery
(2-10 years)
Pre-clinical Testing
Laboratory and animal testing
Phase 1
20-80 healthy volunteers - safety and dosage
Phase 2
100-300 patient volunteers efficacy & safety
Phase 3
3,000-5,000 patient volunteers used to monitor
adverse reactions to long-term use
FDA Review/
Approval
Years
0
2
4
6
8
10
Cost = $1.3B/new drug
12
14
16
Productivity is Decreasing
Source: Tufts Center for the Study of Drug development, PhRMA
Industry Driver: Externalization
PHARMA
CHEM CRO
SYNTHESIZE
REGISTER
DESIGN
DISTRIBUTE
ASSAY
DISTRIBUTE
REPORT
PHARMA
CHEM
SYNTHESIZE
BIO CRO
Selectively
Integrated
Model
DESIGN
DATA CRO
Fully Internal
Model
PHARMA
Cost pressures, disruptive technologies, and other forces
often drive business processes to be externalized.
BIO
ASSAY
REGISTER
REPORT
DATA
Opportunities
Academia
Co-PIs, Institutions
Biotech
Partnerships, JBVs
Pharma
Alliances, Acquisitions
6
Opportunities
Academia
Biotech
Tech. Transfer, Start-ups
Pharma
Tech. Transfer, Acquisitions
7
Pistoia Alliance:
Description and Purpose
Mission
To streamline pre-competitive workflow
elements of pharmaceutical research and
development by specifying common business
terms, relationships and processes
Goal
• Develop taxonomies and vocabularies, application
interface specifications, data dictionaries, data
models, etc.
• Establish standards that will be embraced by
producers and consumers of pre-competitive
workflows
Pistoia Alliance: Membership
as of: August 26, 2009
>65 Individuals from 18 member organizations
Technology Trends Supporting eHealth
SOA
EMR
SaaS
Digital Workflow
PaaS
Digitization of
Health
Information
Cloud computing
Smart Apps
EHR
IaaS
PHR
Health Outcomes
Registries
Semantic Web
Digital Paper
Holographic
Storagec
Health Xchanges
Webservices
Personal Wellness
Plans
E-mail
Mobile IP
Personal Agents
Internet of Thingsc
GPS
Unified Communications
XMPP
4G,
LTE
IPv6, IPSec
Self Monitoring
Device
Mobile Payments
Health devices
Convergence
Ultra WideBand
Search VOIP Smartphones
Telehealth
Portals
Personal Assist Devices
Mobile Broadcast
3D UI
Ambient
Social Networks
Quantum
wiMax
Networking
Communities
Remote Monitoring
Cryptography
Telemedicine
Rapid Diagnostic Kits
RFID
RxAuthentication
Nano Photonics
Low Power Senors
Nanofibers
Imaging sensors
Biometric Senors
Behavior Sensors
Senor Nets(atom+,
Optical Diagnostics
Zigbee, Blue Lite)
Digitization
of Health
Communication
Decreasing
Costs of
Sensors
DNA Sequencing
Microfuidics
Decreasing
Cost of DNA
Sequencing
BioPhotonics
DTC Genetic Testing
Biomarker
Microarrays
OpenSource
(Hadoop,
Crossbow)
Increased
Computational
Analytics
Capabilities
PreImplantationGenetic
Diagnosis
Personal Genome
Record
Dx-Rx Kits
Molecular Imaging
Predictive Models
Real-time analytics
BioMedical
Modeling
Utility Computing
Grid Computing
Now
Solution/Service/Product
2011
Social Mining
2012
2015
2020+
Technologies
10
eHealth Focused Portfolio
Patient-centric
1a
Health & Wellness
Consumer Electronics
2a
Care provision
augmentation
1b
Health & Wellness SelfManagement Services
2b
Clinical Decision
Support Aids
New Product
and Services
Keas
Well Being / Nokia / iPhone
Provider-centric
Business
Diversification
beyond
Pharma
PACeR
Clinical Data
Flow and
Uses
3a
Uses of Clinical Data for R&D
3b
Adverse Event Reporting Utility
DAER/ASTER
Maccabi
3c
Health Economics Analytics
Business
Innovation
within
Pharma
eHealth Strategic Priority Areas for 2010 need to be developed and validated in concert with the
BUs, RUs, Divisions, and the Leadership Team
11
The Evolving Pfizer R&D Ecosystem
 Evolving paradigm for the discovery of medicines (Collaborative)
 A vision that points towards open innovation and collaborations
 Open research model to collectively share scientific expertise
 Enhance speed of drug discovery beyond individual resource capabilities (Speed)
 Limited research budgets and capabilities driving greater shared resources
 Goal to see all partners succeed by accelerating the SCIENCE
 Synergize Pfizer’s strengths with Research Partners (Knowledge)
 Pair Pfizer’s design, cutting edge tools, synthetic excellence with research partners (academics, not-forprofits, venture capitalists, or biotechs) to develop break through science, novel targets, and indications of
unmet medical need
 Current example of academic and not-for-profits partners (Discover and Publish)
 Drive to publish in top journal with science receiving high visibility and interest
Body clock mouse study suggests new drug
potential
Mon, Aug 23 2010
By Kate Kelland
LONDON (Reuters) - Scientists have used experimental drugs being
developed by Pfizer to reset and restart the body clock of mice in a lab
and say their work may offer clues on a range of human disorders, from
a few months ago we entered into a collaboration
jetlag to bipolar disorder.
with
the giant pharmaceutical industry Pfizer to test some
of
their leading molecules for potential relevance to
HD.
Contacts:
 Travis Wager (travis.t.wager@pfizer.com)
 Paul Galatsis (paul.galatsis@pfizer.com)
Emerging Technology Watch List
Horizon 1
Mobility
Digital Platforms
Enterprise Federated Infrastructure
Integration Services
Collaboration and Interconnectivity
Disruptive Business Innovation
Horizon 2
Horizon 3